AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17698900
Drug: vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin (100 mg) without glibenclamide (5 mg)
Trial: 17698900
Drug: glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide (5 mg)
Trial: 12609779
Drug: Cryotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy plus transplantation of cultured melanocytes (CC)
Trial: 12609779
Drug: Only cryotherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only cryotherapeutic treatment (OC)
Trial: 10588768
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) and praziquantel (40 mg/kg body weight)
Trial: 8941458
Drug: Two-injection scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-injection scheme (regimen A)
Trial: 8941458
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glibenclamide with one injection of NPH insulin at bedtime (regimen B)
Trial: 8941458
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glibenclamide with one injection of NPH insulin before breakfast (regimen C)
Trial: 8941458
Drug: Overall insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overall insulin treatment
Trial: 8941458
Drug: Combined insulin-sulfonylurea
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined insulin-sulfonylurea treatment
Trial: 1949134
Drug: Recombinant sporozoite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant sporozoite vaccine
Trial: 31140114
Drug: Ticagrelor pediatric
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor pediatric tablets taken whole
Trial: 31140114
Drug: Ticagrelor pediatric
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor pediatric tablets suspended in water
Trial: 31140114
Drug: Ticagrelor pediatric
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor pediatric tablets and granules for oral suspension
Trial: 23646469
Drug: Qingyang Toujie
RxNorm normalized name: BENZODODECINIUM BROMIDE 2 g in 500 mL EXTRACORPOREAL LIQUID [Youjie Weishi Antibacterial Hand Wash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingyang Toujie Mixture (QTM) in combination with prednisone tablet
Trial: 23646469
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with prednisone tablet
Trial: 19180891
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment with density 1 settings
Trial: 19180891
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment with density 2 settings
Trial: 19180891
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment with density 3 settings
Trial: 17419458
Drug: Cardioversion management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioversion management principles; specific details on dosage and duration not available.
Trial: 10960627
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone acetate/10 microg ethinyl E2
Trial: 10960627
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone acetate/5 microg ethinyl E2
Trial: 10960627
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg norethindrone acetate/1 microg ethinyl E2, 0.5 mg norethindrone acetate/2.5 microg ethinyl E2, 1 mg norethindrone acetate/5 microg ethinyl E2
Trial: 1638587
Drug: Cefprozil 500
RxNorm normalized name: cefprozil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil 500 mg once daily (or 20 mg/kg once daily) for 5 to 10 days
Trial: 1638587
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg three times daily (or 20 mg/kg daily in three equal doses) for 5 to 10 days
Trial: 6143736
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg propranolol i.v.
Trial: 6143736
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg mepindolol sulfate i.v.
Trial: 30466891
Drug: Custirsen added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Custirsen added to first-line chemotherapy with docetaxel
Trial: 20426957
Drug: Guaifenesin compound
RxNorm normalized name: guaiFENesin compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaifenesin compound pseudoephedrine hydrochloride oral solution
Trial: 20426957
Drug: Ambroxol hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol hydrochloride oral solution
Trial: 10404707
Drug: Nonresponders during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders during pharmacotherapy
Trial: 7551920
Drug: CDDP (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP (120 mg/m2 day 1) + etoposide (100 mg/m2 days 1‐3) every 3 weeks (PE‐‐arm A)
Trial: 7551920
Drug: CDDP (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP (120 mg/m2 every 4 weeks) + mitomycin (8 mg/m2 days 1, 29, 71) + vindesine (3 mg/m2 days 1, 8, 15, 22 every 2 weeks) (MVP‐‐arm B)
Trial: 7551920
Drug: CDDP (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP (120 mg/m2 day 1) + mitomycin (6 mg/m2 day 1) + ifosfamide (3 g/m2 day 2) every 3 weeks (MIC‐‐arm C)
Trial: 28732826
Drug: Glycopyrrolate/formoterol fumarate
RxNorm normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler (GFF MDI) 2.4/9.6 mug
Trial: 28732826
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 mug
Trial: 20078201
Drug: Mandibular symphysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular symphysis bone grafting followed by postoperative orthodontic treatment
Trial: 9819039
Drug: rFVIIa (NovoSeven)
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (NovoSeven) administered at home
Trial: 7648636
Drug: China-mode Hepatitis
RxNorm normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: China-mode Hepatitis A attenuated live vaccine
Trial: 339935
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg three times a day)
Trial: 339935
Drug: Mianserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (10 mg three times a day)
Trial: 30661847
Drug: Yoga-CaRe program
RxNorm normalized name: PEPPLUS SPECIAL SKIN CARE LIFTING PROGRAM KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga-CaRe program (13 sessions supervised by an instructor and encouragement to self-practice daily)
Trial: 25832425
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg, po)
Trial: 21696982
Drug: NV1FGF (riferminogene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NV1FGF (riferminogene pecaplasmid) administered intramuscularly
Trial: 19476405
Drug: Intranasal phototherapy
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal phototherapy (allergy reliever SN‐206) used three times a day for 14 days
Trial: 8453387
Drug: Medication discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication discharge planning program (experimental group)
Trial: 3530897
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg nocte (once at night)
Trial: 29794099
Drug: Coordination exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordination exercises with concurrent mental tasks
Trial: 15821888
Drug: HAART (Highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART (Highly Active Antiretroviral Therapy) for six months
Trial: 7899367
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for small cell lung carcinoma
Trial: 144378
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered amine fluorides
Trial: 29508695
Drug: HMB-FA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-FA (3 g/d)
Trial: 25052410
Drug: Doxylamine-vitamin B6
RxNorm normalized name: doxylamine / vitamin B6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxylamine-vitamin B6 combination (Diclectin)
Trial: 23033348
Drug: Prethrombolytic antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prethrombolytic antihypertensive treatment (AHT)
Trial: 23033348
Drug: No prethrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prethrombolytic antihypertensive treatment (AHT)
Trial: 15965279
Drug: Intramuscular iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron (200 mg daily)
Trial: 8676931
Drug: Three-drug group
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug group (rifabutin 600 mg daily, ethambutol, clarithromycin 1000 mg twice daily)
Trial: 8676931
Drug: Three-drug group
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug group (rifabutin 600 mg)
Trial: 8676931
Drug: Four-drug group
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug group (rifampin, ethambutol, clofazimine, ciprofloxacin)
Trial: 8676931
Drug: Three-drug group
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug group (rifabutin 300 mg)
Trial: 6287835
Drug: No mineral
RxNorm normalized name: Multi-Vitamin No Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mineral supplements (Control)
Trial: 28201821
Drug: Cane group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cane group (using a cane daily whenever walking for 12 weeks)
Trial: 26273472
Drug: Group-based Mindfulness-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 26273472
Drug: Individual internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual internet-based Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 20846363
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human follicle-stimulating hormone
Trial: 9972772
Drug: PGE1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 at a dose of 0.02 microg x kg(‐1) x min(‐1) (PG20 group)
Trial: 9972772
Drug: PGE1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 at a dose of 0.05 microg x kg(‐1) x min(‐1) (PG50 group)
Trial: 8775774
Drug: Locally applied
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally applied vaginal conjugated estrogen cream
Trial: 28106471
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% bromfenac sodium
Trial: 24396024
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg for 8 weeks
Trial: 24396024
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ongoing antihypertensive treatment)
Trial: 18381951
Drug: DMXAA (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXAA (doses of 6 to 4,900 mg/m², administered as a 20-minute i.v. infusion weekly or every 3 weeks)
Trial: 19321521
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care consisting of 10 minutes of hand therapy three times a week
Trial: 11339782
Drug: No diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diclofenac suppository (Control)
Trial: 2890728
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg APM/kg body weight
Trial: 2890728
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg body weight as aspartame (APM)
Trial: 27565253
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase support using vaginal progesterone gel (n = 202)
Trial: 24002227
Drug: Individual cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive-behavioral therapy (CBT) based on the modified Coping Cat Program
Trial: 24002227
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual intervention
Trial: 22247123
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg every 12 hours)
Trial: 22247123
Drug: Vancomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (15 mg/kg every 12 hours)
Trial: 20674827
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 microg daily)
Trial: 18235151
Drug: Sarpogrelate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate (300 mg/d)
Trial: 23782492
Drug: Nocturnal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal continuous positive airway pressure (CPAP) treatment
Trial: 14673984
Drug: Tacrolimus 2
RxNorm normalized name: Tacrolimus 200 microgram granules for oral suspension sachet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 2 mg
Trial: 14673984
Drug: Tacrolimus 3
RxNorm normalized name: Tacrolimus 300 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 3 mg
Trial: 11166502
Drug: Standard or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard or non-enhanced treatment (control group).
Trial: 8996671
Drug: Individual biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual biological factors (age, hand volume, hand thickness)
Trial: 1479133
Drug: 1 h
RxNorm normalized name: Type 1 H substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 h of morning light treatment (about 7000 lux)
Trial: 1479133
Drug: 1 h
RxNorm normalized name: Type 1 H substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 h of morning placebo treatment (deactivated negative ion generator)
Trial: 6361287
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone (1,000-mg bolus and daily thereafter for ten days)
Trial: 6361287
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose methylprednisolone (100-mg bolus and daily thereafter for ten days)
Trial: 31345170
Drug: Telephone counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone counseling for caregivers and multicomponent therapy for cognitively impaired persons in day-care centers.
Trial: 30189000
Drug: Electronic home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electronic home medication review tool (before admission)
Trial: 30189000
Drug: Electronic home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electronic home medication review tool (after admission)
Trial: 17686105
Drug: Immunotherapy for
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy for allergic rhinoconjunctivitis
Trial: 15776297
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg i.v. administered at 1 and 9 hours postoperatively
Trial: 15776297
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg i.v.
Trial: 9659670
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine application (17.5 mg day‐1)
Trial: 9659670
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine application (35 mg day‐1)
Trial: 8087519
Drug: 30 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 cisplatin weekly + radiotherapy
Trial: 8087519
Drug: 6 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/m2 cisplatin daily + radiotherapy
Trial: 2789927
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of oxytocin (0.33 u min‐1)
Trial: 29207479
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: MOM (start fortification >50 mL/day) and preterm formula
Trial: 22283892
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months daily rifampin (4RMP)
Trial: 22283892
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months daily isoniazid (9INH)
Trial: 16389540
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 2 weeks
Trial: 15541850
Drug: Rhophylac 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhophylac 300 (300 microg dose) administered either intravenously or intramuscularly
Trial: 9372670
Drug: Nebulized DSCG
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized DSCG 20 mg every 6 hours from Day 3 to Day 28
Trial: 9372670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 cc NS) every 6 hours from Day 3 to Day 28
Trial: 9372670
Drug: Nebulized DSCG
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized DSCG 20 mg
Trial: 9372670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 cc NS)
Trial: 1609045
Drug: Guanfacine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 0.5 mg daily
Trial: 31943843
Drug: In silico
RxNorm normalized name: DRESSING,BIATAIN SILICONE ADH FOAM 7X7IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In silico drug screening for potential inhibitory drug molecules
Trial: 26645515
Drug: Moxibustion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion therapy (Group A)
Trial: 21233256
Drug: Pharmacotherapy management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy management and/or disease management including motivational interviewing (MI) counseling every 6 months over 2 years
Trial: 18274885
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (SP)
Trial: 10922131
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily)
Trial: 10922131
Drug: Concurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily via separate inhalers)
Trial: 31779994
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (100 ml/day) for 9.28±3.75 days followed by Shenmai capsule (3.6 g/day) for 30 days in addition to cardiac rehabilitation
Trial: 27806972
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) 1315 mg catechins (843 mg EGCG), 4 capsules daily for 12 months
Trial: 27806972
Drug: Placebo, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 4 capsules daily for 12 months
Trial: 18473339
Drug: Rational-emotive behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-emotive behavior therapy (REBT)